Search Results - Claire Wainwright
- Showing 1 - 20 results of 45
- Go to Next Page
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
Determination of the Minimal Clinically Important Difference Scores for the Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Scale in Two Populations of Patients With Cyst... by Alexandra L. Quittner, Avani C. Modi, Claire Wainwright, Kelly Otto, Jean Kirihara, A. Bruce Montgomery
Published 2009Revisão -
9
Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis by J.S. Elborn, Bonnie W. Ramsey, Michael Boyle, Michael W. Konstan, Xiaohong Huang, Gautham Marigowda, David Waltz, Claire Wainwright
Published 2016Artigo -
10
-
11
Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor by Patrick A. Flume, Claire Wainwright, D. Elizabeth Tullis, Sally Rodriguez, Minoo Niknian, Mark Higgins, Jane C. Davies, Jeffrey S. Wagener
Published 2017Artigo -
12
-
13
Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa by Claire Wainwright, Alexandra L. Quittner, David E. Geller, C. Nakamura, J.L. Wooldridge, R.L. Gibson, Sarah Lewis, A. Bruce Montgomery
Published 2011Artigo -
14
-
15
-
16
Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial by Jane C. Davies, Claire Wainwright, Gregory S. Sawicki, Mark N. Higgins, Daniel Campbell, Christopher Harris, Paul Panorchan, Eric L. Haseltine, Simon Tian, Margaret Rosenfeld
Published 2020Artigo -
17
-
18
Pneumonia in the first 2 years of life, and asthma in preschool‐age children by José Carlos Santos, Linjie Zhang, Paula K. Menegatti, Camila S. Guasselli, Celso C.M. Filho, Lina R.D.M. Maito, Marina F. Ferreira, Monallisa C. Mariani, Claire Wainwright
Published 2011Artigo -
19
Evidence for Spread of a Clonal Strain of <i>Pseudomonas aeruginosa</i> among Cystic Fibrosis Clinics by David Armstrong, Scott C. Bell, Michael Robinson, Peter T.P. Bye, Barbara Rose, Colin Harbour, Crystal Lee, Helen Service, Michael D. Nissen, Melanie W. Syrmis, Claire Wainwright
Published 2003Carta -
20
Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1 by Susanna A. McColley, Michael W. Konstan, Bonnie W. Ramsey, J.S. Elborn, Michael Boyle, Claire Wainwright, David Waltz, Montserrat Vera‐Llonch, Gautham Marigowda, John Jiang, Jaime Rubin
Published 2018Artigo
Search Tools:
Related Subjects
Medicine
Internal medicine
Cystic fibrosis
Biology
Genetics
Pathology
Cystic fibrosis transmembrane conductance regulator
Bacteria
Ivacaftor
Pediatrics
Pseudomonas aeruginosa
Gastroenterology
Alternative medicine
Gene
Microbiology
Placebo
Randomized controlled trial
Respiratory system
Adverse effect
Clinical trial
Lung
Anesthesia
Clinical endpoint
Bronchiolitis
Confidence interval
Genotype
Sputum
Tuberculosis
Exacerbation
Inhalation